TLR9 expression is related to immune activation but is impaired in individuals with chronic immune activation.
Millions of individuals in developing countries are infected with helminths and other chronic infectious diseases, such as HIV-1, which lead to persistent immune activation and unbalanced immune state. We have suggested that the capacity of chronically immune activated individuals to protect themselves, cope with infections, and mount protective immunity following vaccination, is highly impaired. Here we examined the expression of toll-like receptor 9 (TLR9), as an essential component in the recognition of immunostimulating bacterial CpG-DNA motifs, in different subsets of human peripheral blood mononuclear cells (PBMC) obtained from chronically immune activated and non-activated individuals. TLR9 expression was correlated to immune cell activation and was upregulated following phytohemagglutinin or anti-CD3 activation. PBMC obtained from chronically immune activated individuals had a different overall pattern of TLR9 expression, including reduced upregulation of this receptor following additional immune activation, and diminished responsiveness to CpG-DNA stimulation, in comparison to non-activated individuals. These differences may partly account for the reduced capacity of chronically immune activated individuals to mount effective immune responses and strengthen the notion that the host immune background should be considered in the design and trial of potential adjuvants and vaccines.
Ayash-Rashkovsky
Mila
M
Ruth Ben-Ari Institute of Clinical Immunology, Kaplan Medical Center, Hebrew University Hadassah Medical School, Rehovot 76100, Israel. Mila_Ayashrashkovsky@dfci.harvard.edu
Bentwich
Zvi
Z
Borkow
Gadi
G
D000293:Adolescent; D000328:Adult; D000818:Animals; D017252:CD3 Complex / Q000276:immunology; D002469:Cell Separation; D017690:Cell Transplantation; D018899:CpG Islands / Q000276:immunology*; D004269:DNA, Bacterial / Q000276:immunology; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D007107:Immune System / Q000502:physiology*; D016898:Interferon-alpha / Q000276:immunology; D018664:Interleukin-12 / Q000276:immunology; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000276:immunology*; D008213:Lymphocyte Activation; D008297:Male; D051379:Mice; D008875:Middle Aged; D010835:Phytohemagglutinins / Q000276:immunology; D051217:Toll-Like Receptor 9 / Q000378:metabolism*; D015854:Up-Regulation
D017252:CD3 Complex; D004269:DNA, Bacterial; D016898:Interferon-alpha; D010835:Phytohemagglutinins; C495371:TLR9 protein, human; D051217:Toll-Like Receptor 9; D018664:Interleukin-12